Venetoclax plus hypomethylating agents versus intensive chemotherapy for hematological relapse of myeloid malignancies after allo-HSCT.

Front Oncol · 2023 · PMC10079210 · PMID 37035180

Europe PMC DOI

hedged sentence

0.0780

closest p · 1.6× alpha

0.0780

boldest claim

The sentences

showed a trendP=0.078so close (0.05 < p ≤ 0.1)

In this study, ELN adverse stratification only showed a trend towards reducing survival (HR=2.469 (95% CI 0.904-6.745), P=0.078).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.